Pembrolizumab Shows Further Promise for Melanoma In a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected. by Brad Jones Forward Look Tackling Drug Resistance Researchers are studing new ways to keep treatments working longer. by Stephen Ornes Survivor Profile Living in the Here and Now A metastatic melanoma survivor is hopeful but realistic as new treatments become available. by Jenny Song Forward Look Cancer Immunotherapies Continue to Make Headway Drugs that harness the power of the immune system gain new approvals. by Alexandra Goho Survivor Profile Knowing Her Options When Christina McEvoy was diagnosed with stage IV melanoma, she took the reins of her care, traveling more than 600 miles for treatment and returning home to help other melanoma survivors. by Melissa Davlin First Person Keeping Sight of Hope A survivor keeps an eye on what's ahead after a rare cancer diagnosis. by Sue Russell Cancer Talk 2018 SABCS: Choosing the Right Treatment Studies presented at the 2018 San Antonio Breast Cancer Symposium investigate when patients with early-stage breast cancer or precancerous breast conditions benefit from receiving less intense treatment. by Kate Yandell Treating Cancer Based on Its Genetics, Not Its Location Medical oncologist and sarcoma specialist George D. Demetri explains the significance of the recent approval of the oral drug Vitrakvi based on tumor genetics. by Anna Azvolinsky Coping With Head and Neck Cancer Patients with head and neck cancer often face physical, social and emotional issues that can add to existing mental health problems or give rise to new ones. by Cheryl Platzman Weinstock Coordinating Care A caregiver offers tips for staying on top of appointments and test results when a loved one is receiving care from multiple providers. by Tara Rosenzweig More Posts